Merck (MRK) Said to be Interested in Relypsa (RLYP) - Source
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Plug Power COO resigns to join another company
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
Relypsa (RLYP) Could Be Next High-Profile Takeout, Says Citi
November 6, 2015 10:09 AM ESTRelypsa (NASDAQ: RLYP) opened higher Friday after AstraZeneca (NYSE: AZN) announced a deal to acquire peer ZS Pharma (NASDAQ: ZSPH). The deal announcement stoked speculation Relypsa could be next a topic that was discussed in a research note by analysts at Citi.
Citi sees ZS Pharma's ZS-9 and Relypsa's Veltassa each... More
AstraZeneca (AZN) to Acquire ZS Pharma (ZSPH) in $2.7B Deal
November 6, 2015 6:36 AM ESTAstraZeneca (NYSE: AZN) announced today that it has entered into a definitive agreement to acquire ZS Pharma (NASDAQ: ZSPH), a biopharmaceutical company based in San Mateo, California. ZS Pharma uses its proprietary ionÂ-trap technology to develop novel treatments for hyperkalaemia (high potassium levels), a serious condition of elevated potassium in the bloodstream, typically associated with chronic kidney disease (CKD) and chronic heart failure (CHF).
The transaction will give AstraZeneca access to the potassium-binding compound ZS-9, a potential best-in-class treatment for hyperkalaemia, a condition associated with increased mortality in CKD and CHF. ZS-9 is under regulatory review by the US Food and Drug Administration with a Prescription Drug User Fee Act goal date of 26 May 2016. A submission for European Marketing Application Authorisation is planned by the end of 2015. Current estimates for global peak year sales of ZS-9 exceed $1 billion.
The acquisition continues AstraZenecas track record of targeted business... More
